Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; its reference list is not available; 59 of the 233 sources its claims cite were checked for support.

Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?

Open access
Gogineni, Prathima, Melson, Eka, Papamargaritis, Dimitris, Davies, Melanie · 2024 · Expert Opinion on Pharmacotherapy

Abstract

INTRODUCTION: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have changed the landscape of type 2 diabetes (T2D) management due to their cardio-renal benefits, their glucose-lowering efficacy and weight loss (WL) maintenance. However, the response to GLP-1 RA monotherapy is heterogeneous. Additionally, the majority of GLP-1 RAs are injectable treatments. Oral GLP-1 RAs and injectable combinations of GLP-1 with other entero-pancreatic hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon and amylin) are under development for T2D and obesity management. AREAS COVERED: Herein, we review the data on (i) oral GLP-1 RAs (oral semaglutide 25/50 mg and orforglipron) and (ii) dual/triple agonists (tirzepatide, cagrilintide 2.4 mg/semaglutide 2.4 mg, survodutide, mazdutide, retatrutide) that have recently completed phase 3 trials for T2D or are currently in phase 3 clinical trials. Tirzepatide is the first approved dual agonist (GLP-1/GIP) for T2D and obesity management. EXPERT OPINION: We are in a new era in T2D management where entero-pancreatic hormone-based treatments can result in ≥15% WL and euglycemia for many people with T2D. Multiple molecules with different mechanisms of action are under development for T2D, obesity and other metabolic complications. Data on their cardio-renal benefits, long-term efficacy and safety as well as their cost-effectiveness will better inform their position in treatment algorithms.

Overview

CoChat Summary

TL;DR

This narrative review summarizes oral GLP-1 receptor agonists and injectable combinations of entero-pancreatic hormones for adults with type 2 diabetes, highlighting tirzepatide as the first approved dual GLP-1/GIP agonist and multiple phase 2/3 pipeline agents. It concludes that these therapies can achieve euglycemia and ≥15% weight loss for many patients, but long-term safety, cardiovascular/renal outcomes, and cost-effectiveness data are still needed.

Key findings

  • Oral semaglutide 50 mg once daily produced a mean HbA1c reduction of 2.1% and 9.8% weight loss versus 1.3% and 5.4% with oral semaglutide 14 mg; 55% versus 32% achieved HbA1c ≤6.5%, and 42% versus 16% achieved ≥10% weight loss.
  • Orforglipron, an oral non-peptide GLP-1 RA, reduced HbA1c by −1.19% to −2.10% and body weight by up to 9.6% at 45 mg in a 26-week phase 2 trial, with 12–19% discontinuing due to adverse events.
  • Tirzepatide reduced HbA1c by up to 2.6%, with 70–94% achieving HbA1c ≤6.5% at 15 mg; mean weight loss ranged from −11.7 kg to −12.9 kg at 52 weeks, and up to 43% achieved ≥15% weight loss. In SURPASS-2, 38% on tirzepatide 15 mg achieved HbA1c ≤6.5% plus ≥15% weight loss without hypoglycemia versus 7% on semaglutide 1 mg.
  • Among combination agents, cagrisema (cagrilintide 2.4 mg/semaglutide 2.4 mg) reduced HbA1c by −2.2% and weight by 15.6% versus semaglutide 2.4 mg (−1.8%, 5.1%) and cagrilintide 2.4 mg (−0.9%, 8.1%); retatrutide reduced HbA1c up to −2.2% and weight up to 16.9% versus dulaglutide 1.5 mg (−1.4%, 2%) and placebo (−0.3%, 3%).

Methods

  • Narrative review of published phase 2 and phase 3 clinical trials of oral GLP-1 RAs (oral semaglutide 25/50 mg, orforglipron) and dual/triple entero-pancreatic hormone agonists (tirzepatide, cagrisema, survodutide, mazdutide, retatrutide) in adults with type 2 diabetes and/or obesity.
  • Data are summarized in tables of trial design, baseline characteristics, efficacy outcomes (HbA1c, weight loss, blood pressure), and safety outcomes (adverse events, serious adverse events, discontinuations).
  • Main analysis is a qualitative synthesis of trial results, ongoing phase 3 programs, and expert opinion on positioning, knowledge gaps, and future directions.

Limitations

  • The paper states that long-term safety and efficacy, cardiovascular and renal outcomes, cost-effectiveness, and effects on lean muscle mass require further investigation; phase 2 trials had short follow-up (16–36 weeks) without evidence of weight-loss plateau.
  • The paper notes that most phase 2/3 trials in type 2 diabetes were conducted in populations with obesity (mean baseline BMI 32–36 kg/m², except the mazdutide study in a Chinese population), so efficacy in lean people with type 2 diabetes is not adequately studied.
  • Evident from the text: this is a narrative review without a systematic search or meta-analysis, and many included agents are still in phase 3, so comparative efficacy and safety versus approved therapies remain incomplete.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1080/14656566.2024.2356254

Cites

Statistics

Nothing to recompute.

Figures

Figure 1. Actions of entero-pancreatic hormones on different organs.
Figure 1. Actions of entero-pancreatic hormones on different organs.CC BY-NC-ND · PubMed Central
Figure 2. Approved molecules and those in the pipeline (currently undergoing phase 3 trials) for type 2 diabetes and/or obesity.
Figure 2. Approved molecules and those in the pipeline (currently undergoing phase 3 trials) for type 2 diabetes and/or obesity.CC BY-NC-ND · PubMed Central
Figure 3. Efficacy results with the novel molecules on HbA1C and WL from phase 3 and phase 2 clinical trials in people with type 2 diabetes.
Figure 3. Efficacy results with the novel molecules on HbA1C and WL from phase 3 and phase 2 clinical trials in people with type 2 diabetes.CC BY-NC-ND · PubMed Central
Figure 4. The journey of evidence for the novel molecules for type 2 diabetes and/or obesity – the ongoing phase 3 and phase 4 clinical trials.
Figure 4. The journey of evidence for the novel molecules for type 2 diabetes and/or obesity – the ongoing phase 3 and phase 4 clinical trials.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

36 Valid · 6 Not valid · 118 Not checked · 14 Own results and interpretations

104 more claims · 29 with their cited sources checked

Create a free account to see all 174 claims and to verify the 171 references still open.

See all claims — free account
  • Probably not a substantial claim. 20
  • It may state two separate claims as one. 52

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 99 · Cited by 32

Research works printed but not linked: 2

  1. Pfizer announces topline phase 2b results of oral GLP-1R agonist danuglipron in adults with obesity. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-2b-results-oral-glp-1r
  2. Pharmathene Inc. Historical Press Releases. Altimmune announces positive results from week 24 interim analysis of pemvidutide momentum phase 2 obesity trial and 12-week phase 1b type 2 diabetes safety trial. Available from: https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-positive-results-week-24-interim-analysis

Metadata

Authors
Gogineni, P., Melson, E., Papamargaritis, D., & Davies, M.
Affiliations
University of Leicester (GB)
Corresponding author
Papamargaritis, Dimitris
Venue
Expert Opinion on Pharmacotherapy
Published
2024-05-02
Volume
25
Issue
7
Pages
801-818
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W4396977424
Cited by
32
References
99
Citations by year
2026: 13 · 2025: 12 · 2024: 7
FWCI
1.88
Type
journal article
Language
en
Open access
Locations
  • Expert Opinion on Pharmacotherapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by-nc-nd)
Funders
he National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, oral GLP-1 receptor agonists, semaglutide, orforglipron, tirzepatide, cagrilintide, survodutide, mazdutide, retatrutide, glucose-dependent insulinotropic polypeptide, glucagon, amylin, obesity treatment, weight loss, dual agonist, treatment algorithm
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Adult, Animals, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Obesity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? https://app.cochat.ai/papers/10.1080/14656566.2024.2356254
The paper
Gogineni, P., Melson, E., Papamargaritis, D., & Davies, M. (2024). Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2024.2356254

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.